# Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy

> **NCT05909761** · — · RECRUITING · sponsor: **Amgen** · enrollment: 60 (estimated)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder
- Pregnancy Related

## Interventions

- **DRUG:** UPLIZNA

## Key facts

- **NCT ID:** NCT05909761
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2032-10-31
- **Final completion:** 2032-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05909761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05909761, "Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05909761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*